Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2007-10-23
2007-10-23
Campell, Bruce R. (Department: 1648)
Chemistry: molecular biology and microbiology
Vector, per se
C435S091400, C435S091410, C435S091420, C424S093100
Reexamination Certificate
active
10900067
ABSTRACT:
The present invention relates to compositions comprising a novel recombinant virus which replicates selectively in cells or tissues that are hypoxic or have an activated HIF pathway. The novel compositions of the invention comprise a recombinant virus genetically engineered to have a hypoxia/HIF-responsive element, or a multiplicity of such elements, operably linked to a promoter which is in turn operably linked to a nucleic acid(s) encoding a peptide(s) which regulates or modulates replication of the virus and/or encode a therapeutic molecule. The invention also includes constructs useful for screening of agents which interact with proteins or genes in the hypoxia-inducible pathway or are jointly translated under hypoxia and animal models useful for monitoring a variety of hypoxic conditions in a non-invasive manner.
REFERENCES:
patent: 4958007 (1990-09-01), Alroy et al.
patent: 5382427 (1995-01-01), Plunkett et al.
patent: 5401490 (1995-03-01), Wiebe et al.
patent: 5482923 (1996-01-01), Maione
patent: 5677178 (1997-10-01), McCormick
patent: 5681706 (1997-10-01), Anderson et al.
patent: 5728379 (1998-03-01), Martuza et al.
patent: 5834306 (1998-11-01), Webster et al.
patent: 5840686 (1998-11-01), Chader et al.
patent: 5843404 (1998-12-01), Koch et al.
patent: 5846528 (1998-12-01), Podsakoff et al.
patent: 5846945 (1998-12-01), McCormick
patent: 5854205 (1998-12-01), O'Reilly et al.
patent: 5858351 (1999-01-01), Podsakoff et al.
patent: 5871726 (1999-02-01), Henderson et al.
patent: 5882914 (1999-03-01), Semenza
patent: 5942434 (1999-08-01), Ratcliffe et al.
patent: 5952226 (1999-09-01), Aebischer et al.
patent: 5977058 (1999-11-01), Aggarwal et al.
patent: 6024688 (2000-02-01), Folkman et al.
patent: 6046031 (2000-04-01), Ni et al.
patent: 6080578 (2000-06-01), Bischoff et al.
patent: 6124131 (2000-09-01), Semenza
patent: 6130071 (2000-10-01), Alitalo et al.
patent: 6174861 (2001-01-01), O'Reilly et al.
patent: 6184035 (2001-02-01), Csete et al.
patent: 6197293 (2001-03-01), Henderson et al.
patent: 6211163 (2001-04-01), Podsakoff et al.
patent: 6218179 (2001-04-01), Webster et al.
patent: 6222018 (2001-04-01), Semenza
patent: 6288024 (2001-09-01), Bouck et al.
patent: 6900049 (2005-05-01), Yu et al.
patent: WO95/24208 (1995-09-01), None
patent: WO96/20276 (1996-07-01), None
patent: WO98/05797 (1998-02-01), None
patent: WO99/23216 (1999-05-01), None
patent: WO 00/15820 (2000-03-01), None
Ruan et al. (Neoplasm 1999, vol. 1, No. 5, pp. 431-437.
Minchenko A et al. Cell Mol Biol Res. 1994 vol. 40m, No. 1, pp. 35-39.
Wei et al. J. Neuroviol. 1998, vol. 4, No. 2, pp. 237-241.
Griga et al. Hepatogastroeenterology 2000, vol. 47, No. 36, pp. 1604-1607.
Alemany, R. et al. (Jul. 2000) “Replicative Adenoviruses For Cancer Therapy;”Nat. Biotech. 18:723-727.
Bischoff, J.R. et al. (1996) “An Adenovirus Mutant That Replicates Selectively in p53-Deficient Human Tumor Cells;”Science274:373-376.
Brown, J.M. et al. (1998) “The Unique Physiology of Solid Tumors: Opportunities (and Problems) for Cancer Therapy;”Cancer Res. 58:1408-1416.
Chapman, J.D. (1991) “Measurement of Tumor Hypoxia by Invasive and Non-Invasive Procedures: A Review of Recent Clinical Studies;”Radiother. Oncol. Suppl. 20:13-19.
Chapman, J.D. (1984) “The Detection and Measurement of Hypoxic Cells in Solid Tumors;”Cancer54(11): 2441-2449.
Cuevas et al. (2003) “Specific Oncolytic Effect of a New Hypoxia-Inducible Factor-Dependent Replicative Adenovirus on von Hippel-Lindau-Defective Renal Cell Carcinomas,”Cancer Res. 63:6877-6884.
De Fraipont, F. et al. (Sep. 2001) “Thrombospondins and Tumor Angiogenesis;”TRENDS. Mol. Med. 7(9): 401-407.
Goodrum. F.D. et al. (1998) “p53 Status Does Not Determine Outcome of E1B 55-Kilodalton Mutant Adenovirus Lytic Infection;”J. Virol. 72(12):9479-9490.
Grau, C. et al. (1988) “Effect of Cancer Chemotherapy on the Hypoxic Fraction of a Solid Tumor Measured Using a Local Tumor Control Assay;”Radiother. Oncol. 13:301-309.
Gray, L.H. et al. (1953) “The Concentration of Oxygen Dissolved in Tissues At The Time of Irradiation As A Factor In RadioTherapy;”Br. J. Radiol. 26(312): 638-648.
Hasegawa, T. et al. (1987) “Increase in Tumor pO2by Perfluorochemicals and Carbogen;”Int. J. Radiat. Oncol. Biol. Phys. 13:569-574.
He, T.C. et al. (1998) “A Simplified System for Generating Recombinant Adenoviruses;”Proc. Natl. Acad. Sci. 95:2509-2514.
Ido, A. et al. (Apr. 2001) “Gene Therapy Targeting for Hepatocellular Carinoma: Selective and Enhanced Suicide Gene Expression Regulated by a Hypoxia-Inducible Enhancer Linked to a Human. α.-Fetoprotein Promotor;”Cancer Research61:3016-3021.
Jain, R. (1988) “Determinants of Tumor Blood Flow: A Review;”Cancer Res. 48:2641-2658.
Kaur et al. (2003) “Brain Angiogenesis Inhibitor 1 Is Differentially Expressed in Normal Brain and Glioblastoma Independently of p53 Expression,”Am .J. Pathol. 162:19-27.
Kirn, D. (Dec. 2000) “Replication-Selective Oncolytic Adenoviruses: Virotherapy Aimed at Genetic Targets in Cancer;”Oncogene19:6660-6669.
Markert, J.M. et al. (May 2000) “Conditionally Replicating Herpes Simplex Virus mutant, G207 for the Treatment of Malignant Glioma: Results of a Phase I Trial;”Gene Ther. 7:867-874.
O'Reilly, M.S. et al. (1994) “Angiostatin: A Circulating Endothelial Cell Inhibitor That Suppresses Angiogenesis and Tumor Growth;”Cold Spring Harbor Symposia on Quantitative BiologyLIX:471-482.
Parker, J.N. et al. (Feb. 2000) “Engineered Herpes Simplex Virus Expressing IL-12 in the Treatment of Experimental Murine Brain Tumors;”PNAS97:2208-2213.
DE Post and Van Meir (2001) “Generation of Bidirectional Hypoxia/HIF-Responsive Expression Vectors to Target Gene Expression to Hypoxic Cells,” GeneTherapy8:1801-1807.
Rodriguez, R. et al. (1997) “Prostate Attenuated Replication Competent Adenovirus (ARCA) CN706: A Selective Cytotoxic for Prostate-Specific Antigen-Positive Prostate Cancer Cells;”Cancer Res. 57:2559-2563.
Rothmann, T. et al. (1998) “Replication of ONYX-015, a Potential Anticancer Adenovirus, Is Independent of p53 Status in Tumor Cells;”J. Virol. 72(12):9470-9478.
Ruan, H. et al. (May-Jun. 2001) “A Hypoxia-Regulated Adeno-Associated Virus Vector for Cancer-Specific Gene Therapy;”Neoplasia3(3):255-263.
Ruan, H. et al. “Use of Hypoxia-Related Gene Expression in Tumor-Specific Gene Therapy;”Curr. Opin. Investig. Drugs(Jun. 2001) 2(6):839-834.
Semenza et al. (1998) “From Molecular Biology to Cardiopulmonary Physiology,”Chest114:40S-45S.
Siemann, D.W. et al. (1988) “Characterization of Radiation Resistant Hypoxic Cell Subpopulations in KHT Sarcomas. (ii) Cell Sorting;”Br. J. Cancer58:296-300.
Sinkovics, J. et al. (1993) “New Developments in the Virus Therapy of Cancer: A Historical Review;”Intervirology36:193-214.
Song, C.W. et al. (1987) “Increase in pO2and Radiosensitivity of Tumors by Fluosol-DA (20%) and Carbogen;”Cancer Res. 47:442-446.
Teicher, B.A. et al. (1990) “Classification of Antineoplastic Treatments by Their Differential Toxicity Toward Putative Oxygenated and Hypoxic Tumor Subpopulationsin Vivoin the FSaIIC Murine Fibrosarcoma;”Cancer Res. 50:3339-3344.
Vaupel, P. et al. (1987) “Blood Flow, Oxygen Consumption, and Tissue Oxygenation of Human Breast Cancer Xenografts in Nude Rats;”Cancer Res. 47:3496-3503.
Vaupel, P. et al. (1981) “Heterogeneous Oxygen Partial Pressure and pH Distribution in C3H Mouse Mammary Adenocarcinoma;”Cancer Res. 41:2008-2013.
Yang D.J. et al. (1995) “Development of F-18-Labeled Fluoroerythronitroimidazole as a PET Agent for Imaging Tumor Hypoxia;”Radiology194(3):795-800.
Baron, U. et al. (1995) “Co-regulation of two gene activities by tetracycline via a bidirectional promoter&
Nicholson Ainsley C.
Post Dawn E.
Van Meir Erwin G.
Campell Bruce R.
Emory University
Greenlee Winner and Sullivan P.C.
Li Bao Qun
LandOfFree
Viruses targeted to hypoxic cells and tissues does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Viruses targeted to hypoxic cells and tissues, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Viruses targeted to hypoxic cells and tissues will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3847092